A generic drug is developed with the same dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use as a brand-name medication. Generics are known as bioequivalent to the name-brand drug, so they demonstrate the same degree of clinical benefit.
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
Date: November 4, 2020 Time: 6:00am (PDT), 9:00am (EDT) The Global Scar Society was formed to gain consensus for and promote best practice in the prevention and treatment of abnormal & e...
Date: November 2, 2020 Time: 8:00am PST. Rapid and accurate microbial diagnostic information can change treatment courses and outcomes for patients inflicted with infections. The limitation...
Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
Date: October 28, 2020 Time: 7:00am (PDT), 10:00am (EDT) Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half o...
DATE: October 27th, 2020 TIME: 6:00am PT Bruker proudly introduces the latest member of the MALDI Biotyper® product family, the MALDI Biotyper sirius one. Bruker‘s newest sirius sy...
This session introduces basic concepts of imaging-based high-throughput screening (HTS) and high-throughput profiling assay development. Imaging-based HTS assays are designed to evaluate a d...
To identify genetic variants in archival human samples, researchers need a powerful NGS platform that can accommodate input DNA and RNA that is often low quality and/or low quantity. This ch...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
Date: November 4, 2020 Time: 6:00am (PDT), 9:00am (EDT) The Global Scar Society was formed to gain consensus for and promote best practice in the prevention and treatment of abnormal & e...
Date: November 2, 2020 Time: 8:00am PST. Rapid and accurate microbial diagnostic information can change treatment courses and outcomes for patients inflicted with infections. The limitation...
Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
Date: October 28, 2020 Time: 7:00am (PDT), 10:00am (EDT) Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half o...
DATE: October 27th, 2020 TIME: 6:00am PT Bruker proudly introduces the latest member of the MALDI Biotyper® product family, the MALDI Biotyper sirius one. Bruker‘s newest sirius sy...
This session introduces basic concepts of imaging-based high-throughput screening (HTS) and high-throughput profiling assay development. Imaging-based HTS assays are designed to evaluate a d...
To identify genetic variants in archival human samples, researchers need a powerful NGS platform that can accommodate input DNA and RNA that is often low quality and/or low quantity. This ch...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
The treatment of cancer has remarkably improved because of increased knowledge of the molecular abnormalities that drive human cancer growth. This has led to the development of ever more eff...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
